Review




Structured Review

Creative Biolabs ovcar 8 cells
Ovcar 8 Cells, supplied by Creative Biolabs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovcar 8 cells/product/Creative Biolabs
Average 86 stars, based on 1 article reviews
ovcar 8 cells - by Bioz Stars, 2026-05
86/100 stars

Images



Similar Products

96
ATCC non small cell lung cancer nci h226 6 05 breast cancer t 47d 6 03 ovarian cancer ovcar
Non Small Cell Lung Cancer Nci H226 6 05 Breast Cancer T 47d 6 03 Ovarian Cancer Ovcar, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non small cell lung cancer nci h226 6 05 breast cancer t 47d 6 03 ovarian cancer ovcar/product/ATCC
Average 96 stars, based on 1 article reviews
non small cell lung cancer nci h226 6 05 breast cancer t 47d 6 03 ovarian cancer ovcar - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

95
IROA Technologies LLC cv ovcar 8 iroa is ovcar 4 cell ovcar 8 cell ovcar 4 cell
Cv Ovcar 8 Iroa Is Ovcar 4 Cell Ovcar 8 Cell Ovcar 4 Cell, supplied by IROA Technologies LLC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cv ovcar 8 iroa is ovcar 4 cell ovcar 8 cell ovcar 4 cell/product/IROA Technologies LLC
Average 95 stars, based on 1 article reviews
cv ovcar 8 iroa is ovcar 4 cell ovcar 8 cell ovcar 4 cell - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

86
Creative Biolabs ovcar 8 cells
Ovcar 8 Cells, supplied by Creative Biolabs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovcar 8 cells/product/Creative Biolabs
Average 86 stars, based on 1 article reviews
ovcar 8 cells - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

90
Creative Biolabs human ovarian carcinoma cell line ovcar-8
Human Ovarian Carcinoma Cell Line Ovcar 8, supplied by Creative Biolabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ovarian carcinoma cell line ovcar-8/product/Creative Biolabs
Average 90 stars, based on 1 article reviews
human ovarian carcinoma cell line ovcar-8 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

95
IROA Technologies LLC ovcar 8 cell
Ovcar 8 Cell, supplied by IROA Technologies LLC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovcar 8 cell/product/IROA Technologies LLC
Average 95 stars, based on 1 article reviews
ovcar 8 cell - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

98
ATCC cell lines u2os female atcc rrid cvcl 0042 ovcar 8
Figure 2. PARG inhibition causes PARP1 aggregation in response to laser-induced DNA damage (A) Western blot showing the overexpression of C-terminal GFP-tagged PARP1 in a <t>U2OS</t> PARP1/ cell line. (B) Schematic overview of live cell imaging to monitor PARP1 recruitment and dissociation in the PARP1-eGFP cell line. (C) Cells were pre-treated with 10 mM PARGi for 1 h and subjected to laser-induced damage. Images were taken every 30 s for 30 frames and representative images are shown at pre-bleach, and 1 min and 10 min post-bleach. Scale bar: 10 mm. (D) Bright spot intensity was quantified and normalized to maximum PARP1 intensity across 8 different experiments and data are presented as mean ± SD. ***p < 0.001 (Welch’s two-sample t test). (E) PARP1 signal area at the bright spot was quantified over time in the PARGi-treated condition. (F) PARP1 aggregates were quantified over time in the PARGi-treated and untreated conditions. (G) PARP1 aggregate size (in microns2) was plotted on the left y axis and aggregate intensity (in arbitrary units a.u.) was plotted on the right y axis over time. Once PARP1 aggregates are formed and detected, their size and intensity remain stable. See also Figure S3; Video S1.
Cell Lines U2os Female Atcc Rrid Cvcl 0042 Ovcar 8, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell lines u2os female atcc rrid cvcl 0042 ovcar 8/product/ATCC
Average 98 stars, based on 1 article reviews
cell lines u2os female atcc rrid cvcl 0042 ovcar 8 - by Bioz Stars, 2026-05
98/100 stars
  Buy from Supplier

97
ATCC cells adherent ovarian cancer cell lines ovcar 8
Figure 2. PARG inhibition causes PARP1 aggregation in response to laser-induced DNA damage (A) Western blot showing the overexpression of C-terminal GFP-tagged PARP1 in a <t>U2OS</t> PARP1/ cell line. (B) Schematic overview of live cell imaging to monitor PARP1 recruitment and dissociation in the PARP1-eGFP cell line. (C) Cells were pre-treated with 10 mM PARGi for 1 h and subjected to laser-induced damage. Images were taken every 30 s for 30 frames and representative images are shown at pre-bleach, and 1 min and 10 min post-bleach. Scale bar: 10 mm. (D) Bright spot intensity was quantified and normalized to maximum PARP1 intensity across 8 different experiments and data are presented as mean ± SD. ***p < 0.001 (Welch’s two-sample t test). (E) PARP1 signal area at the bright spot was quantified over time in the PARGi-treated condition. (F) PARP1 aggregates were quantified over time in the PARGi-treated and untreated conditions. (G) PARP1 aggregate size (in microns2) was plotted on the left y axis and aggregate intensity (in arbitrary units a.u.) was plotted on the right y axis over time. Once PARP1 aggregates are formed and detected, their size and intensity remain stable. See also Figure S3; Video S1.
Cells Adherent Ovarian Cancer Cell Lines Ovcar 8, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cells adherent ovarian cancer cell lines ovcar 8/product/ATCC
Average 97 stars, based on 1 article reviews
cells adherent ovarian cancer cell lines ovcar 8 - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

97
ATCC adherent ovarian cancer cell lines ovcar 8
Combinatorial treatment effect of olaparib and GW in a translational approach using primary <t>OvCa</t> spheroids. Primary cells from two BRCA 1 (UF-364; UF-510) and one BRCA 2 mutated patient (UF-357) were grown as spheroids in ULA plates and analyzed for their response to olaparib and additional treatment either GI or GW. The solvent DMSO has been used as a control. (A) Relative (rel.) caspase activity was increased following treatment with olaparib and GW compared to olaparib mono-treatment. Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. (B) Representative Brightfield (left) and CellTox Green (right) images of UF-357; UF-364 and UF-510 following the indicated treatment conditions, which generated the strongest combinatorial effect are displayed (UF-357: 0/100 µM olaparib; UF-364: 0/10 µM olaparib; UF-510: 0/200 µM olaparib). Scalebar: 250 μm.
Adherent Ovarian Cancer Cell Lines Ovcar 8, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adherent ovarian cancer cell lines ovcar 8/product/ATCC
Average 97 stars, based on 1 article reviews
adherent ovarian cancer cell lines ovcar 8 - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

90
CEM Corporation ovcar-8 cell line
Combinatorial treatment effect of olaparib and GW in a translational approach using primary <t>OvCa</t> spheroids. Primary cells from two BRCA 1 (UF-364; UF-510) and one BRCA 2 mutated patient (UF-357) were grown as spheroids in ULA plates and analyzed for their response to olaparib and additional treatment either GI or GW. The solvent DMSO has been used as a control. (A) Relative (rel.) caspase activity was increased following treatment with olaparib and GW compared to olaparib mono-treatment. Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. (B) Representative Brightfield (left) and CellTox Green (right) images of UF-357; UF-364 and UF-510 following the indicated treatment conditions, which generated the strongest combinatorial effect are displayed (UF-357: 0/100 µM olaparib; UF-364: 0/10 µM olaparib; UF-510: 0/200 µM olaparib). Scalebar: 250 μm.
Ovcar 8 Cell Line, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovcar-8 cell line/product/CEM Corporation
Average 90 stars, based on 1 article reviews
ovcar-8 cell line - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Human Protein Atlas csc markers in ovcar-8 and skov-3 cell lines
Combinatorial treatment effect of olaparib and GW in a translational approach using primary <t>OvCa</t> spheroids. Primary cells from two BRCA 1 (UF-364; UF-510) and one BRCA 2 mutated patient (UF-357) were grown as spheroids in ULA plates and analyzed for their response to olaparib and additional treatment either GI or GW. The solvent DMSO has been used as a control. (A) Relative (rel.) caspase activity was increased following treatment with olaparib and GW compared to olaparib mono-treatment. Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. (B) Representative Brightfield (left) and CellTox Green (right) images of UF-357; UF-364 and UF-510 following the indicated treatment conditions, which generated the strongest combinatorial effect are displayed (UF-357: 0/100 µM olaparib; UF-364: 0/10 µM olaparib; UF-510: 0/200 µM olaparib). Scalebar: 250 μm.
Csc Markers In Ovcar 8 And Skov 3 Cell Lines, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/csc markers in ovcar-8 and skov-3 cell lines/product/Human Protein Atlas
Average 90 stars, based on 1 article reviews
csc markers in ovcar-8 and skov-3 cell lines - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Figure 2. PARG inhibition causes PARP1 aggregation in response to laser-induced DNA damage (A) Western blot showing the overexpression of C-terminal GFP-tagged PARP1 in a U2OS PARP1/ cell line. (B) Schematic overview of live cell imaging to monitor PARP1 recruitment and dissociation in the PARP1-eGFP cell line. (C) Cells were pre-treated with 10 mM PARGi for 1 h and subjected to laser-induced damage. Images were taken every 30 s for 30 frames and representative images are shown at pre-bleach, and 1 min and 10 min post-bleach. Scale bar: 10 mm. (D) Bright spot intensity was quantified and normalized to maximum PARP1 intensity across 8 different experiments and data are presented as mean ± SD. ***p < 0.001 (Welch’s two-sample t test). (E) PARP1 signal area at the bright spot was quantified over time in the PARGi-treated condition. (F) PARP1 aggregates were quantified over time in the PARGi-treated and untreated conditions. (G) PARP1 aggregate size (in microns2) was plotted on the left y axis and aggregate intensity (in arbitrary units a.u.) was plotted on the right y axis over time. Once PARP1 aggregates are formed and detected, their size and intensity remain stable. See also Figure S3; Video S1.

Journal: Structure (London, England : 1993)

Article Title: PARG inhibition induces nuclear aggregation of PARylated PARP1.

doi: 10.1016/j.str.2024.09.006

Figure Lengend Snippet: Figure 2. PARG inhibition causes PARP1 aggregation in response to laser-induced DNA damage (A) Western blot showing the overexpression of C-terminal GFP-tagged PARP1 in a U2OS PARP1/ cell line. (B) Schematic overview of live cell imaging to monitor PARP1 recruitment and dissociation in the PARP1-eGFP cell line. (C) Cells were pre-treated with 10 mM PARGi for 1 h and subjected to laser-induced damage. Images were taken every 30 s for 30 frames and representative images are shown at pre-bleach, and 1 min and 10 min post-bleach. Scale bar: 10 mm. (D) Bright spot intensity was quantified and normalized to maximum PARP1 intensity across 8 different experiments and data are presented as mean ± SD. ***p < 0.001 (Welch’s two-sample t test). (E) PARP1 signal area at the bright spot was quantified over time in the PARGi-treated condition. (F) PARP1 aggregates were quantified over time in the PARGi-treated and untreated conditions. (G) PARP1 aggregate size (in microns2) was plotted on the left y axis and aggregate intensity (in arbitrary units a.u.) was plotted on the right y axis over time. Once PARP1 aggregates are formed and detected, their size and intensity remain stable. See also Figure S3; Video S1.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit anti-PARP1 Cell Signaling Technology Cat#9542; RRID: AB_2160739 Rabbit anti-PAR Millipore Cat#MABE1031; RRID: AB_2665467 Rabbit anti-SIRT6 Cell Signaling Technology Cat#12486; RRID: AB_2636969 Rabbit anti-Histone H3 GeneTex Cat#GTX122148; RRID: AB_10633308 Mouse anti-GAPDH Proteintech Cat#60004; RRID: AB_2737588 Mouse anti-PARG Millipore Cat#MABS61; RRID:AB_10806473 Mouse anti-PARP1 R&D Biosystems, discontinued Cat#4338-MC; RRID: AB_354246 Rabbit anti-XRCC1 Cell Signaling Technology Cat#2375; RRID: AB_2218471 Mouse anti-PAR Abcam Cat#ab14459; RRID: AB_301239 Rabbit anti-cleaved PARP (Asp214) Cell Signaling Technology Cat#5625; RRID: AB_10699459 Rabbit Anti-b-tubulin Cell Signaling Technology Cat#2146; RRID: AB_2210545 Anti-rabbit IgG HRP-linked Cell Signaling Technology Cat#7074; RRID: AB_2099233 Anti-mouse IgG HRP-linked Thermo Fisher Scientific Cat#31432; RRID: AB_228302 Mouse anti-phospho-Histone H2A.X (Ser139) Millipore Cat#05–636; RRID: AB_309864 Rabbit anti-53BP1 Novus Biologicals Cat#NB100-904; RRID: AB_10002714 Alexa Fluor 488 goat anti-mouse Thermo Fisher Scientific Cat#A-11001; RRID: AB_2534069 Alexa Fluor 555 goat anti-mouse Thermo Fisher Scientific Cat#A-21422; RRID: AB_2535844 Alexa Fluor 555 goat anti-rabbit Thermo Fisher Scientific Cat#A-21428; RRID: AB_2535849 Alexa Fluor 647 goat anti-rabbit Thermo Fisher Scientific Cat#A-21245; RRID: AB_2535813 Anti-phospho-Histone H2A.X (Ser139), Alexa Fluor 488 Conjugate Millipore Cat#05-636-AF488; RRID:N/A Bacterial and virus strains MAX Efficiency DH5a Competent Cells Invitrogen Cat#18258012 PARP1 exon 7-targeting lentivirus Dr. Gregory Breuer, Yale University N/A Chemicals, peptides, and recombinant proteins Dimethyl sulfoxide Sigma-Aldrich Cat#D4540 Methyl methanesulfonate Sigma-Aldrich Cat#129925 PDD 00017273 (PARGi) Tocris Cat#5952 Olaparib MedChem Express Cat#HY-10162 5-Bromo-20-Deoxyuridine Sigma-Aldrich Cat#B5002 Talazoparib Selleckchem Cat#S7048 Hydrogen peroxide Sigma-Aldrich Cat#H1009 Temozolomide Selleckchem Cat#S1237 Z-VAD-FMK Selleckchem Cat#S7023 Critical commercial assays Subcellular Fractionation Kit for Cultured Cells Thermo Fisher Scientific Cat#78840 Deposited data Original western blot images This study Mendeley Data https://doi.org/10.17632/ ktpzmk93yg.1 Experimental models: Cell lines U2OS (female) ATCC RRID:CVCL_0042 OVCAR-8 (female) DCTD Tumor Repository RRID:CVCL_1629 U2OS PARP1 / (female) This study N/A (Continued on next page) e1 Structure 32, 2083–2093.e1–e5, November 7, 2024

Techniques: Inhibition, Western Blot, Over Expression, Live Cell Imaging

Figure 4. PARP1 catalytic activity is required for the formation of PARP1 aggre- gates (A) Representative images of the validation of the U2OS PAR sensor cell line with 5 mM olaparib treatment. Upon olaparib treatment, no PAR sensor signal is detected 1 min after laser-induced damage. (B) Bright spot intensity was quantified and normalized to maximum PAR intensity across 4 different experiments, ***p < 0.001 (Welch’s two- sample t test). (C) Representative images of PARP1-eGFP, APLF- PBZ-mCherry, and the merged images taken pre- bleach, and 15 min and 60 min after laser-induced damage. Cells were pre-treated with 10 mM PARGi for 1 h. The co-localization of PARP1 with PAR and PAR with PARP1 aggregates were represented as percentages calculated using ImageJ with a co- localization tolerance of 1 pixel. Data are pre- sented as mean ± SD, n = 4 nuclei. Scale bar: 5 mm. (D) Schematic of full-length PARP1 protein showing the catalytic domain and the site of the point mu- tation. Western blot showing overexpression of PARP1 catalytic variants, E988D, producing me- dium PAR chains, and E988A, producing no PAR chains in the PARP1/ cell line. The PARP1 cat- alytic variants show reduced PAR chain expression compared to PARP1 wildtype (WT). (E) Representative images of PARP1-WT, -E988A, and -E988D-eGFP cells pre-bleach and 7.5 min post-bleach after pre-treatment with 10 mM PARGi for 1 h. (F) Quantification of normalized PARP1 intensity at the site of damage with and without PARGi treat- ment after laser-induced damage over 15 min. n = 3 nuclei, n.s. = not significant (Welch’s two-sample t test). (G) Quantification of PARP1 aggregates in PARP1- WT, -E988A, and -E988D-eGFP cell lines with and without PARGi treatment at 7.5 min after laser- induced damage. PARP1 aggregates form only in the PARP1 catalytically proficient cell line. Data are presented as mean ± SD, n = 3 nuclei, *p < 0.05 (two-tailed unpaired t test). Scale bar: 10 mm. See also Figure S5.

Journal: Structure (London, England : 1993)

Article Title: PARG inhibition induces nuclear aggregation of PARylated PARP1.

doi: 10.1016/j.str.2024.09.006

Figure Lengend Snippet: Figure 4. PARP1 catalytic activity is required for the formation of PARP1 aggre- gates (A) Representative images of the validation of the U2OS PAR sensor cell line with 5 mM olaparib treatment. Upon olaparib treatment, no PAR sensor signal is detected 1 min after laser-induced damage. (B) Bright spot intensity was quantified and normalized to maximum PAR intensity across 4 different experiments, ***p < 0.001 (Welch’s two- sample t test). (C) Representative images of PARP1-eGFP, APLF- PBZ-mCherry, and the merged images taken pre- bleach, and 15 min and 60 min after laser-induced damage. Cells were pre-treated with 10 mM PARGi for 1 h. The co-localization of PARP1 with PAR and PAR with PARP1 aggregates were represented as percentages calculated using ImageJ with a co- localization tolerance of 1 pixel. Data are pre- sented as mean ± SD, n = 4 nuclei. Scale bar: 5 mm. (D) Schematic of full-length PARP1 protein showing the catalytic domain and the site of the point mu- tation. Western blot showing overexpression of PARP1 catalytic variants, E988D, producing me- dium PAR chains, and E988A, producing no PAR chains in the PARP1/ cell line. The PARP1 cat- alytic variants show reduced PAR chain expression compared to PARP1 wildtype (WT). (E) Representative images of PARP1-WT, -E988A, and -E988D-eGFP cells pre-bleach and 7.5 min post-bleach after pre-treatment with 10 mM PARGi for 1 h. (F) Quantification of normalized PARP1 intensity at the site of damage with and without PARGi treat- ment after laser-induced damage over 15 min. n = 3 nuclei, n.s. = not significant (Welch’s two-sample t test). (G) Quantification of PARP1 aggregates in PARP1- WT, -E988A, and -E988D-eGFP cell lines with and without PARGi treatment at 7.5 min after laser- induced damage. PARP1 aggregates form only in the PARP1 catalytically proficient cell line. Data are presented as mean ± SD, n = 3 nuclei, *p < 0.05 (two-tailed unpaired t test). Scale bar: 10 mm. See also Figure S5.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit anti-PARP1 Cell Signaling Technology Cat#9542; RRID: AB_2160739 Rabbit anti-PAR Millipore Cat#MABE1031; RRID: AB_2665467 Rabbit anti-SIRT6 Cell Signaling Technology Cat#12486; RRID: AB_2636969 Rabbit anti-Histone H3 GeneTex Cat#GTX122148; RRID: AB_10633308 Mouse anti-GAPDH Proteintech Cat#60004; RRID: AB_2737588 Mouse anti-PARG Millipore Cat#MABS61; RRID:AB_10806473 Mouse anti-PARP1 R&D Biosystems, discontinued Cat#4338-MC; RRID: AB_354246 Rabbit anti-XRCC1 Cell Signaling Technology Cat#2375; RRID: AB_2218471 Mouse anti-PAR Abcam Cat#ab14459; RRID: AB_301239 Rabbit anti-cleaved PARP (Asp214) Cell Signaling Technology Cat#5625; RRID: AB_10699459 Rabbit Anti-b-tubulin Cell Signaling Technology Cat#2146; RRID: AB_2210545 Anti-rabbit IgG HRP-linked Cell Signaling Technology Cat#7074; RRID: AB_2099233 Anti-mouse IgG HRP-linked Thermo Fisher Scientific Cat#31432; RRID: AB_228302 Mouse anti-phospho-Histone H2A.X (Ser139) Millipore Cat#05–636; RRID: AB_309864 Rabbit anti-53BP1 Novus Biologicals Cat#NB100-904; RRID: AB_10002714 Alexa Fluor 488 goat anti-mouse Thermo Fisher Scientific Cat#A-11001; RRID: AB_2534069 Alexa Fluor 555 goat anti-mouse Thermo Fisher Scientific Cat#A-21422; RRID: AB_2535844 Alexa Fluor 555 goat anti-rabbit Thermo Fisher Scientific Cat#A-21428; RRID: AB_2535849 Alexa Fluor 647 goat anti-rabbit Thermo Fisher Scientific Cat#A-21245; RRID: AB_2535813 Anti-phospho-Histone H2A.X (Ser139), Alexa Fluor 488 Conjugate Millipore Cat#05-636-AF488; RRID:N/A Bacterial and virus strains MAX Efficiency DH5a Competent Cells Invitrogen Cat#18258012 PARP1 exon 7-targeting lentivirus Dr. Gregory Breuer, Yale University N/A Chemicals, peptides, and recombinant proteins Dimethyl sulfoxide Sigma-Aldrich Cat#D4540 Methyl methanesulfonate Sigma-Aldrich Cat#129925 PDD 00017273 (PARGi) Tocris Cat#5952 Olaparib MedChem Express Cat#HY-10162 5-Bromo-20-Deoxyuridine Sigma-Aldrich Cat#B5002 Talazoparib Selleckchem Cat#S7048 Hydrogen peroxide Sigma-Aldrich Cat#H1009 Temozolomide Selleckchem Cat#S1237 Z-VAD-FMK Selleckchem Cat#S7023 Critical commercial assays Subcellular Fractionation Kit for Cultured Cells Thermo Fisher Scientific Cat#78840 Deposited data Original western blot images This study Mendeley Data https://doi.org/10.17632/ ktpzmk93yg.1 Experimental models: Cell lines U2OS (female) ATCC RRID:CVCL_0042 OVCAR-8 (female) DCTD Tumor Repository RRID:CVCL_1629 U2OS PARP1 / (female) This study N/A (Continued on next page) e1 Structure 32, 2083–2093.e1–e5, November 7, 2024

Techniques: Activity Assay, Biomarker Discovery, Western Blot, Over Expression, Expressing, Two Tailed Test

Figure 5. PARP1 aggregates are associated with cell death responses (A) Representative images of U2OS PARP1-eGFP cells in response to the indicated damaging treatments. Cells were treated with 0.00125% MMS and 10 mM PARGi for 24 h. Diffuse cytoplasmic PARP1 signal (indicated with an asterisk) is observed only in cells with nuclear PARP1 aggregates. (B) Percentage of cells containing cytoplasmic PARP1 was quantified across the treatment conditions for 3 independent experiments. Data are presented as mean ± SD, n R 40 nuclei per condition, **p < 0.01 (two-tailed unpaired t test). (C) U2OS PARP1-eGFP cells were treated as indicated and the cytoplasmic and nuclear-soluble fractions were isolated. SIRT6 and b-tubulin represent the nuclear and cytoplasmic loading controls respectively. Cleaved PARP1 signal was observed in both the nuclear and cytoplasmic fractions in the PARGi and MMS co-treatment condition. In our plasmid, full-length PARP1 tagged with eGFP corresponds to approximately 141 kDa. After cleavage at the Asp214 site of PARP1, the larger fragment would be 141-24 = 117 kDa, which aligns with our results.

Journal: Structure (London, England : 1993)

Article Title: PARG inhibition induces nuclear aggregation of PARylated PARP1.

doi: 10.1016/j.str.2024.09.006

Figure Lengend Snippet: Figure 5. PARP1 aggregates are associated with cell death responses (A) Representative images of U2OS PARP1-eGFP cells in response to the indicated damaging treatments. Cells were treated with 0.00125% MMS and 10 mM PARGi for 24 h. Diffuse cytoplasmic PARP1 signal (indicated with an asterisk) is observed only in cells with nuclear PARP1 aggregates. (B) Percentage of cells containing cytoplasmic PARP1 was quantified across the treatment conditions for 3 independent experiments. Data are presented as mean ± SD, n R 40 nuclei per condition, **p < 0.01 (two-tailed unpaired t test). (C) U2OS PARP1-eGFP cells were treated as indicated and the cytoplasmic and nuclear-soluble fractions were isolated. SIRT6 and b-tubulin represent the nuclear and cytoplasmic loading controls respectively. Cleaved PARP1 signal was observed in both the nuclear and cytoplasmic fractions in the PARGi and MMS co-treatment condition. In our plasmid, full-length PARP1 tagged with eGFP corresponds to approximately 141 kDa. After cleavage at the Asp214 site of PARP1, the larger fragment would be 141-24 = 117 kDa, which aligns with our results.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit anti-PARP1 Cell Signaling Technology Cat#9542; RRID: AB_2160739 Rabbit anti-PAR Millipore Cat#MABE1031; RRID: AB_2665467 Rabbit anti-SIRT6 Cell Signaling Technology Cat#12486; RRID: AB_2636969 Rabbit anti-Histone H3 GeneTex Cat#GTX122148; RRID: AB_10633308 Mouse anti-GAPDH Proteintech Cat#60004; RRID: AB_2737588 Mouse anti-PARG Millipore Cat#MABS61; RRID:AB_10806473 Mouse anti-PARP1 R&D Biosystems, discontinued Cat#4338-MC; RRID: AB_354246 Rabbit anti-XRCC1 Cell Signaling Technology Cat#2375; RRID: AB_2218471 Mouse anti-PAR Abcam Cat#ab14459; RRID: AB_301239 Rabbit anti-cleaved PARP (Asp214) Cell Signaling Technology Cat#5625; RRID: AB_10699459 Rabbit Anti-b-tubulin Cell Signaling Technology Cat#2146; RRID: AB_2210545 Anti-rabbit IgG HRP-linked Cell Signaling Technology Cat#7074; RRID: AB_2099233 Anti-mouse IgG HRP-linked Thermo Fisher Scientific Cat#31432; RRID: AB_228302 Mouse anti-phospho-Histone H2A.X (Ser139) Millipore Cat#05–636; RRID: AB_309864 Rabbit anti-53BP1 Novus Biologicals Cat#NB100-904; RRID: AB_10002714 Alexa Fluor 488 goat anti-mouse Thermo Fisher Scientific Cat#A-11001; RRID: AB_2534069 Alexa Fluor 555 goat anti-mouse Thermo Fisher Scientific Cat#A-21422; RRID: AB_2535844 Alexa Fluor 555 goat anti-rabbit Thermo Fisher Scientific Cat#A-21428; RRID: AB_2535849 Alexa Fluor 647 goat anti-rabbit Thermo Fisher Scientific Cat#A-21245; RRID: AB_2535813 Anti-phospho-Histone H2A.X (Ser139), Alexa Fluor 488 Conjugate Millipore Cat#05-636-AF488; RRID:N/A Bacterial and virus strains MAX Efficiency DH5a Competent Cells Invitrogen Cat#18258012 PARP1 exon 7-targeting lentivirus Dr. Gregory Breuer, Yale University N/A Chemicals, peptides, and recombinant proteins Dimethyl sulfoxide Sigma-Aldrich Cat#D4540 Methyl methanesulfonate Sigma-Aldrich Cat#129925 PDD 00017273 (PARGi) Tocris Cat#5952 Olaparib MedChem Express Cat#HY-10162 5-Bromo-20-Deoxyuridine Sigma-Aldrich Cat#B5002 Talazoparib Selleckchem Cat#S7048 Hydrogen peroxide Sigma-Aldrich Cat#H1009 Temozolomide Selleckchem Cat#S1237 Z-VAD-FMK Selleckchem Cat#S7023 Critical commercial assays Subcellular Fractionation Kit for Cultured Cells Thermo Fisher Scientific Cat#78840 Deposited data Original western blot images This study Mendeley Data https://doi.org/10.17632/ ktpzmk93yg.1 Experimental models: Cell lines U2OS (female) ATCC RRID:CVCL_0042 OVCAR-8 (female) DCTD Tumor Repository RRID:CVCL_1629 U2OS PARP1 / (female) This study N/A (Continued on next page) e1 Structure 32, 2083–2093.e1–e5, November 7, 2024

Techniques: Two Tailed Test, Isolation, Plasmid Preparation

Combinatorial treatment effect of olaparib and GW in a translational approach using primary OvCa spheroids. Primary cells from two BRCA 1 (UF-364; UF-510) and one BRCA 2 mutated patient (UF-357) were grown as spheroids in ULA plates and analyzed for their response to olaparib and additional treatment either GI or GW. The solvent DMSO has been used as a control. (A) Relative (rel.) caspase activity was increased following treatment with olaparib and GW compared to olaparib mono-treatment. Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. (B) Representative Brightfield (left) and CellTox Green (right) images of UF-357; UF-364 and UF-510 following the indicated treatment conditions, which generated the strongest combinatorial effect are displayed (UF-357: 0/100 µM olaparib; UF-364: 0/10 µM olaparib; UF-510: 0/200 µM olaparib). Scalebar: 250 μm.

Journal: Scientific Reports

Article Title: Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids

doi: 10.1038/s41598-024-78442-y

Figure Lengend Snippet: Combinatorial treatment effect of olaparib and GW in a translational approach using primary OvCa spheroids. Primary cells from two BRCA 1 (UF-364; UF-510) and one BRCA 2 mutated patient (UF-357) were grown as spheroids in ULA plates and analyzed for their response to olaparib and additional treatment either GI or GW. The solvent DMSO has been used as a control. (A) Relative (rel.) caspase activity was increased following treatment with olaparib and GW compared to olaparib mono-treatment. Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. (B) Representative Brightfield (left) and CellTox Green (right) images of UF-357; UF-364 and UF-510 following the indicated treatment conditions, which generated the strongest combinatorial effect are displayed (UF-357: 0/100 µM olaparib; UF-364: 0/10 µM olaparib; UF-510: 0/200 µM olaparib). Scalebar: 250 μm.

Article Snippet: Adherent ovarian cancer cell lines OVCAR-8 (RRID: CVCL_1629 ) , IGROV-1 (RRID: CVCL_1304) and SKOV-3 (RRID: CVCL_0532), purchased from American Type Culture Collection (ATCC) were grown with RPMI-1640 medium containing 10% fetal bovine serum (Gibco Life Technologies), 1% L-Glutamine (Sigma-Aldrich, St. Louis, MO, USA) and penicillin-streptomycin (3000 U pen./30,000 μg str. per 500 mL RPMI-1640; Biochrom).

Techniques: Solvent, Control, Activity Assay, CellTox Assay, Generated